10.60

1.63% 0.17

Bioage Labs Inc (BIOA)

Overview News Price History Discussions Forecast

Bioage Labs Inc stock is traded at $10.60, with a volume of 444.31K. It is up +1.63% in the last 24 hours and down -53.47% over the past month. Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

Previous Close:

$10.43

Open:

$10.37

24h Volume:

444.31K

Relative Volume:

0.55

Market Cap:

$486.51M

Revenue:

$10.32M

Net Income/Loss:

$-89.93M

P/E Ratio:

-4.4049

EPS:

-2.4064

Net Cash Flow:

$-88.63M

1W Performance:

-9.56%

1M Performance:

-53.47%

6M Performance:

-45.84%

1Y Performance:

+137.67%

1-Day Range:

$10.10

$10.63

1-Week Range:

$10.10

$11.89

52-Week Range:

$4.38

$25.95

Bioage Labs Inc Stock (BIOA) Company Profile

Name

Bioage Labs Inc

Sector

Healthcare (1080)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

510-806-1445

Address

5885 HOLLIS STREET, EMERYVILLE

Employee

Twitter

Next Earnings Date

2026-08-05

Latest SEC Filings

BIOA's Discussions on Twitter

Compare BIOA vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BIOA Bioage Labs Inc	10.60	481.00M	10.32M	-89.93M	-88.63M	-2.4064
TAK Takeda Pharmaceutical Co Adr	17.63	55.60B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.77	42.81B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.70	43.16B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	73.79	30.39B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	499.73	21.95B	3.17B	1.29B	1.01B	27.09

Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-27-26	Initiated	Roth Capital	Buy
May-13-26	Initiated	BTIG Research	Buy
Mar-27-26	Initiated	Needham	Buy
Feb-25-26	Initiated	Oppenheimer	Outperform
Feb-18-26	Upgrade	Jefferies	Hold → Buy
Jan-27-26	Initiated	Piper Sandler	Overweight
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Oct-22-25	Upgrade	Citigroup	Neutral → Buy
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-09-24	Downgrade	Citigroup	Buy → Neutral
Dec-09-24	Downgrade	Jefferies	Buy → Hold
Oct-21-24	Initiated	Citigroup	Buy
Oct-21-24	Initiated	Jefferies	Buy
Oct-21-24	Initiated	Morgan Stanley	Overweight

View All

Bioage Labs Inc Stock (BIOA) Latest News

Aug 14, 2026

Cormorant Asset Management (BIOA) discloses 5.38% BioAge Labs ownership stake - Stock Titan

Aug 14, 2026

Aug 13, 2026

214,546 Shares in BioAge Labs, Inc. $BIOA Purchased by Dimensional Fund Advisors LP - MarketBeat

Aug 13, 2026

Aug 12, 2026

BioAge Labs, Inc. (NASDAQ:BIOA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Aug 12, 2026

Aug 11, 2026

Renaissance Technologies LLC Buys 120,188 Shares of BioAge Labs, Inc. $BIOA - MarketBeat

Aug 11, 2026

Aug 10, 2026

We're Not Very Worried About BioAge Labs' (NASDAQ:BIOA) Cash Burn Rate - Moomoo

Aug 10, 2026